SARS-CoV-2-neutralising antibody BGB-DXP593 in mild-to-moderate COVID-19: a multicentre, randomised, double-blind, phase 2 trial.

Because the primary endpoint based on nasopharyngeal swab samples was not met, however, any a priori statistical testing of study endpoints based on saliva samples could only be considered hypothesis generating and a p-value <0.05 nominally significant.

also in 7,732 other papers